COVID‐19 infection in patients with sickle cell disease

Severe acute respiratory syndrome coronavirus 2, also known as COVID‐19, has spread to 184 countries with almost 1.5 million cases as of mid‐April 2020 since first reported (1). The clinical features of this disease are not completely understood, however severe illness is thought to predominantly oc...

Full description

Saved in:
Bibliographic Details
Published in:British Journal of Haematology 2020-06, Vol.189 (5), p.851-852
Main Authors: Hussain, Faiz A., Njoku, Franklin U., Saraf, Santosh L., Molokie, Robert E., Gordeuk, Victor R., Han, Jin
Format: Article
Language:English
Subjects:
Adult
Anemia, Sickle Cell - blood
Anemia, Sickle Cell - pathology
Anemia, Sickle Cell - therapy
Anti-Bacterial Agents - administration & dosage
Betacoronavirus
Blood Transfusion
Coronavirus Infections - blood
Coronavirus Infections - pathology
Coronavirus Infections - therapy
Correspondence
COVID-19
Female
Hematology
Humans
Hydroxychloroquine - administration & dosage
Male
Oxygen - administration & dosage
Pandemics
Pneumonia, Viral - blood
Pneumonia, Viral - pathology
Pneumonia, Viral - therapy
SARS-CoV-2
Sickle cell anemia
Sickle cell disease
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus 2, also known as COVID‐19, has spread to 184 countries with almost 1.5 million cases as of mid‐April 2020 since first reported (1). The clinical features of this disease are not completely understood, however severe illness is thought to predominantly occur in adults with advanced age and those with underlying comorbidities (2). Sickle cell disease (SCD), an immunocompromised condition, puts patients at higher risk for respiratory infections and subsequent pulmonary complications such as acute chest syndrome (ACS) (3).
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16734